Company Overview of W. L. Gore & Associates, Inc.
W. L. Gore & Associates, Inc. manufactures and sells fluoropolymer products for a range of industries. The company offers consumer products, cables and cable assemblies, electronic and electrochemical materials, fabrics, fibers, filtration products, medical solutions and devices, pharmaceutical processing products, sealants, and venting products. It serves aerospace, automotive, chemical processing, computer, telecommunications, test and measurement, electronics, energy, environment, industrial and manufacturing, medical, military, pharmaceutical and biotechnology, semiconductor and microelectronics, and textiles industries. W. L. Gore & Associates, Inc. was founded in 1958 and is based in N...
555 Papermill Road
Newark, DE 19711
Founded in 1958
Key Executives for W. L. Gore & Associates, Inc.
Chief Executive Officer and President
Compensation as of Fiscal Year 2014.
W. L. Gore & Associates, Inc. Key Developments
W. L. Gore & Associates, Inc. Reports Study Confirms GORE® BIO-A® Tissue Reinforcement a Proven Alternative to Biologics in Hernia Repair
Apr 28 15
W. L. Gore & Associates, Inc. announced final results of a long term prospective multicenter study examining the quality of life for patients after complex ventral hernia (VH) repair. Investigators presented their findings in the Complex Open Bioabsorbable Reconstruction of the Abdominal Wall Study, focused on hernia repair with a biosynthetic mesh, at the 2015 World Hernia Conference in Milan, Italy. Patients scheduled to undergo complex VH repair often have a poor quality of life preoperatively because of a GI fistula, mesh infection, or non-healing abdominal wound. GORE BIO-A Tissue Reinforcement provides a unique material option for complex cases because it is designed with the ideal porosity for rapid cellular infiltration and vascularization to generate quality tissue fast. GORE BIO-A Tissue Reinforcement is a uniquely designed web of biocompatible synthetic polymers that the body gradually absorbs, while its 3D matrix of open, highly interconnected pores facilitates tissue generation and healing. As a synthetic tissue scaffold, it is not derived from human or animal tissue but engineered for uniformity, consistency and versatility. Clinical evidence demonstrates that the scaffold is replaced with favorable type I collagen, leaving no permanent material behind. GORE BIO-A Tissue Reinforcement is currently marketed in many countries worldwide. The company's study is possibly one of the first complex VH clinical studies of a 3D biosynthetic mesh to factor in patient satisfaction. With a three-year shelf life and no soaking, refrigeration or tracking required, this versatile material is the easy-to-use performance-proven alternative that offers value for surgeons and hospitals alike. Biologic hernia meshes have a high cost due to the harvesting of tissues from cadavers, pigs, cows, and then the subsequent processing to remove cells to protect patients from possible viral contamination. Most other synthetics, while less expensive, are a permanent addition to the patient’s body. The GORE BIO-A Bioabsorbable Material technology combines the best of the two hernia mesh treatment options, consistently created with no synthetic material left behind, and no risk of viral contamination from tissue-derived biologic materials.
W. L. Gore & Associates, Inc. Announces Completion of Enrollment for the Gore Reduce Clinical Study
Feb 24 15
W. L. Gore & Associates, Inc. announced completion of enrollment for the Gore REDUCE Clinical Study, a prospective, randomized, multi-center, multi-national trial designed to demonstrate safety and effectiveness of the GORE® HELEX® Septal Occluder and GORE® Septal Occluder for PFO closure in patients with a history of cryptogenic stroke or imaging-confirmed transient ischemic attack (TIA). The study includes 65 investigational sites in the US, Canada, UK, Denmark, Norway, Sweden, and Finland that enrolled a combined 664 subjects. All subjects will complete a minimum of two years of follow-up evaluations before analysis of the study endpoints.
Gore Completes Primary Enrollment for the Gore EXCLUDER® Iliac Branch Clinical Study
Feb 17 15
W. L. Gore & Associates, Inc. announced that it has completed primary enrollment in the Gore EXCLUDER Iliac Branch Clinical Study, a prospective, multi-center, non-randomized, single-arm study designed to assess the safety and effectiveness of the GORE® EXCLUDER® Iliac Branch Endoprosthesis in treating common iliac artery aneurysms or aorto-iliac aneurysms. A total of 62 patients have received the device, which completed the required enrollment of 60 set by the Food and Drug Administration (FDA). Additionally, the FDA approved a Continued Access Protocol (CAP) allowing an additional 140 patients to be treated with the device. The CAP also includes use of the GORE EXCLUDER Iliac Branch Endoprosthesis for bilateral placement. An estimated 20% to 40% of patients with abdominal aortic aneurysms have common iliac arteries that also require repair, yet no device has been approved for this treatment indication in the United States. This iliac branch device provides a wider range of patients with access to minimally invasive, endovascular treatment options. The GORE EXCLUDER Iliac Branch Device (iliac branch component and internal iliac component) is used in conjunction with the GORE® EXCLUDER® AAA Endoprosthesis to isolate the common iliac artery from systemic blood flow and preserve blood flow in the external iliac and internal iliac arteries.
Similar Private Companies By Industry
Recent Private Companies Transactions